However, there will be enough supply for seniors and immunocompromised Americans.
“We have a sufficient current stock of vaccines, both in states and pharmacies and other access points around the country and in our central stock for fourth doses, if they are called up this spring for our most vulnerable, including seniors,” Covid in The White House. -19 response coordinator Jeff Zients said in response to a question from CNN during Wednesday’s briefing.
“Where we do not have sufficient doses is later in the year, if science dictates that all Americans should get a booster, or if there is a need for a new formulation of the vaccine, a variant-specific vaccine, for example, then we will not have sufficient supply. , “Zients added, calling the situation” completely unacceptable. “
Dr. Anthony Fauci, President Joe Biden’s chief medical adviser, suggested that other boosters could be approved by the U.S. Food and Drug Administration to the general public “toward early fall” or “late summer,” though he said another booster could approved for a smaller subgroup, “perhaps older” Americans, in the coming weeks.
Zients said there is still adequate supply “in the short term” for Americans who need their first dose, second dose or first booster.
Other top public health officials issued similar warnings as the administration continued to advocate for funding.
Fauci warned that the United States “will not be able to continue to make these purchases” of monoclonal antibody treatments without continued funding.
Dr. Rochelle Walensky, director of the U.S. Centers for Disease Control and Prevention, continued to call funding “critical.”
“If cases arise from the Omicron variant or any other variant, we have the tools – vaccines, boosters, tests and therapies to prepare – but continue to invest in these tools so that they are readily available when we need them. those are still critical, “she said. “From a public health point of view, it is crucial that we continue to give people the tools to keep them, their families and their communities safe.”
Zients also warned that “failure to invest now will leave us with inadequate testing capacity and supply,” calling the consequences of congressional inaction “serious” and “immediate.”
Some of the immediate consequences that have already taken place, he said, include the “phasing out” of funding to support uninsured Americans, as well as “fewer life-saving monoclonal antibody treatments being sent to states” and “fewer treatments available to immunocompromised people.”